Transitioning to OROS® methylphenidate from atomoxetine is effective in children and adolescents with ADHD

Expert Review of Neurotherapeutics

Volumn 11, Issue 4, 2011, Pages 499-508

  Niederkirchner, Käthe ^a   Slawik, Lara ^b   Wermelskirchen, Detlef ^b   Rettig, Klaus ^c   Schäuble, Barbara ^d  

^a Private Practice   (Germany)

^b JANSSEN CILAG GMBH   (Germany)

^c Qualitätssicherung in der Medizin mbH   (Germany)

^d Janssen EMEA   (Germany)

Author keywords

ADHD; children adolescents; OROS methylphenidate; transition

Indexed keywords

ATOMOXETINE; METHYLPHENIDATE;

ABDOMINAL PAIN; ACADEMIC ACHIEVEMENT; ADOLESCENT; ADULT; AGGRESSION; ANOREXIA; ANXIETY DISORDER; ARTICLE; ASTHENIA; ATTENTION DEFICIT DISORDER; BODY WEIGHT; CHILD; CHILD BEHAVIOR; CLINICAL ARTICLE; CONCENTRATION LOSS; DEPRESSION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; HYPERTENSION; INSOMNIA; INTENTION TO TREAT ANALYSIS; MALE; MENTAL INSTABILITY; MULTICENTER STUDY; NAUSEA; NEUROSIS; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PERSONALITY DISORDER; PLAY; PRESCHOOL CHILD; PROSPECTIVE STUDY; QUALITY OF LIFE; RATING SCALE; RESTLESSNESS; SCHOOL CHILD; SIDE EFFECT; SLEEP DISORDER; SOCIAL AVOIDANCE BEHAVIOR; SOCIAL INTERACTION; TACHYCARDIA; TASK PERFORMANCE; TIC; TREATMENT DURATION; VITAL SIGN; VOMITING;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; METHYLPHENIDATE; PROPYLAMINES; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 79953748760     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.11.18     Document Type: Article

References (20)

1. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet 366, 237-248 (2005). (Pubitemid 40981053)
2. Faraone SV, Sergeant J, Gillberg C, Biederman J. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2, 104-113 (2003).
3. Searight HR, Burke JM, Rottnek F. Adult ADHD: evaluation and treatment in family medicine. Am. Fam. Physician 62, 2077-2086, 2091-2092 (2000).
4. Buitelaar J, Medori R. Treating attention-deficit/hyperactivity disorder beyond symptom control alone in children and adolescents: a review of the potential benefits of long-acting stimulants. Eur. Child Adolesc. Psychiatry 19, 325-340 (2010).
5. Danckaerts M, Sonuga-Barke EJS, Banaschewski T et al. The quality of life of children with attention deficit/ hyperactivity disorder: a systematic review. Eur. Child Adolesc. Psychiatry 19, 83-105 (2010).
6. Kemner JE, Starr HL, Ciccone PE, Hooper- Wood CG, Crockett RS. Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study. Adv. Ther. 22, 498-512 (2005). (Pubitemid 43130867)
7. Newcorn JH, Kratochvil CJ, Allen AJ et al. Atomoxetine/methylphenidate Comparative Study Group. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am. J. Psychiatry 165, 721-730 (2008). (Pubitemid 351810541)
8. Conners CK. Rating scales in attention-deficit/hyperactivity disorder: use in assessment and treatment monitoring. J. Clin. Psychiatry 59(Suppl. 7), 24-30 (1998). (Pubitemid 28317219)
9. Conners CK. Clinical use of rating scales in diagnosis and treatment of attention-deficit/hyperactivity disorder. Pediatr. Clin. North Am. 46, 857-870 (1999). (Pubitemid 29477877)
10. Conners CK, Sitarenios G, Parker JD, Epstein JN. The revised Conners' parent rating scale (CPRS-R): factor structure, reliability, and criterion validity. J. Abnorm. Child Psychol. 26, 257-268 (1998). (Pubitemid 28359774)
11. Mattejat F, Remschmidt H. [Assessing the quality of life of children and adolescents with psychiatric disorders - an overview]. Z. Kinder Jugendpsychiatr. Psychother. 26, 183-196 (1998). (Pubitemid 28391547)
12. Mattejat F, Jungmann J, Meusers M et al. [The inventory of life quality in children and adolescents ILC - a pilot study]. Z. Kinder Jugendpsychiatr. Psychother. 26, 174-182 (1998). (Pubitemid 28391546)
13. Mattejat F, Simon B, König U et al. Lebensqualität bei psychisch kranken Kindern und Jugendlichen. Z. Kinder Jugendpsychiatr. Psychother. 31, 293-303 (2003).
14. Jozefiak T, Larsson B, Wichstrøm L, Mattejat F, Ravens-Sieberer U. Quality of Life as reported by school children and their parents: a cross-sectional survey. Health Qual. Life Outcomes 6, 34-45 (2008).
15. Shaffer D, Gould MS, Brasic J et al. A children's global assessment scale (CGAS). Arch. Gen. Psychiatry 40, 1228-1231 (1983). (Pubitemid 13015019)
16. Michelson D, Allen AJ, Busner J et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am. J. Psychiatry 159, 1896-1901 (2002). (Pubitemid 35283256)
17. Hammerness P, Georgiopoulos A, Doyle RL et al. An open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics. J. Child Adolesc. Psychopharmacol. 19, 493-499 (2009).
18. Wilens TE, Hammerness P, Utzinger L et al. An open study of adjunct OROS-methylphenidate in children and adolescents who are atomoxetine partial responders: I. Effectiveness. J. Child Adolesc. Psychopharmacol. 19, 485-492 (2009).
19. Kim HW, Yoon IY, Cho SC et al. The effect of OROS methylphenidate on the sleep of children with attention-deficit/ hyperactivity disorder. Int. Clin. Psychopharmacol. 25, 107-115 (2010).
20. Swanson J, Gupta S, Lam A et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/ hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch. Gen. Psychiatry 60, 204-211 (2003). (Pubitemid 36173129)